ProAir RespiClick: adverse event reports filed with FDA

1,611

reports as suspect product

0% of all reports · about 145 a year

5

reports, 12 months to June 2026

11 in the 12 months before

9.1%

marked serious by the reporter

40.5% across the class

0.7%

record death among outcomes, as reported

12 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of ProAir RespiClick reports recording the termmedian drug in beta2-adrenergic agonist

1. Drug ineffectivethe medicine did not work as expected70%1,127
2. Product physical issuea physical defect in the product8.4%135
3. Device issuea problem with the device5.6%90
4. Dyspnoeashortness of breath5.4%87
5. Device malfunctionthe device did not work properly5%80
6. Medication residue present3.4%54
7. Asthmaasthma3.2%51
8. Product quality issuea problem with the product itself2.8%45
9. Coughcough2.6%42
10. Product use issuea problem in how the product was used2%33
11. Product substitution issuea problem after switching products2%32
12. Drug effect incomplete1.7%28
13. Drug effect decreasedthe medicine had less effect1.7%27
14. Product use in unapproved indicationused for a purpose not on the label1.4%22
15. Device delivery system issuea problem with the delivery system1.3%21
16. Malaisegeneral feeling of being unwell1.2%19
17. Wrong technique in product usage processthe product was used in the wrong way1.2%19
18. Chest discomfortchest discomfort1.1%18
19. Feeling abnormalfeeling odd or not right1.1%17
20. Product cleaning inadequate0.9%15
21. Adverse eventan unwanted medical event, type not specified0.9%14
22. Chest painchest pain0.9%14
23. Product storage errorthe product was stored wrongly0.8%13
24. Wheezingwheezing0.8%13
25. Headachehead pain0.7%12
26. Heart rate increaseda fast heart rate reading0.7%12
27. Intentional product misusedeliberate use not as intended0.7%12
28. Off label useused for a purpose or in a way not on the label0.7%12
29. Product taste abnormalthe product tasted odd0.7%12
30. Condition aggravatedthe condition being treated got worse0.7%11

Top 30 of 137 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the beta2-adrenergic agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 91,817 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 1,611 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the beta2-adrenergic agonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists ProAir RespiClick as a suspect or interacting product; reports listing it only as a concomitant medication (1,055) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.